Free Trial
NASDAQ:CTXR

Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis

Citius Pharmaceuticals logo
$2.19 +0.10 (+4.52%)
Closing price 03:57 PM Eastern
Extended Trading
$2.22 +0.03 (+1.14%)
As of 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Citius Pharmaceuticals Stock (NASDAQ:CTXR)

Key Stats

Today's Range
$1.99
$2.48
50-Day Range
$0.68
$2.10
52-Week Range
$0.65
$26.25
Volume
2.80 million shs
Average Volume
756,713 shs
Market Capitalization
$23.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Consensus Rating
Moderate Buy

Company Overview

Citius Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CTXR MarketRank™: 

Citius Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 531st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Citius Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Citius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Citius Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($4.50) to $1.25 per share.

  • Price to Book Value per Share Ratio

    Citius Pharmaceuticals has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Citius Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.82% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently increased by 103.13%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Citius Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Citius Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.82% of the float of Citius Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Citius Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Citius Pharmaceuticals has recently increased by 103.13%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Citius Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    14 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.70% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 16.88% of the stock of Citius Pharmaceuticals is held by institutions.

  • Read more about Citius Pharmaceuticals' insider trading history.
Receive CTXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CTXR Stock News Headlines

Citius Pharmaceuticals Inc News (CTXR) - Investing.com
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Citius Pharma Announces Direct Offering
Citius Pharmaceuticals expands authorized shares
See More Headlines

CTXR Stock Analysis - Frequently Asked Questions

Citius Pharmaceuticals' stock was trading at $4.00 at the start of the year. Since then, CTXR stock has decreased by 45.1% and is now trading at $2.1950.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.08) by $0.19.

Citius Pharmaceuticals shares reverse split on the morning of Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/14/2025
Today
7/03/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTXR
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$53.00
High Stock Price Target
$100.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+2,510.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.14 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.25 per share
Price / Book
0.20

Miscellaneous

Free Float
9,496,000
Market Cap
$21.58 million
Optionable
Optionable
Beta
1.23

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CTXR) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners